Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,433 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Recruiting Early Phase 1 Interventional

Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas

NCT06829173
View directory record Official record
Conditions
High-Grade Glioma
Interventions
XRD-0394, Radiation Therapy, Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive-Motor Training for AD/ADRD Prevention

NCT07160582
View directory record Official record
Conditions
MCI, Aging
Interventions
Novel CogXergaming Training, Exercise and Education Training Program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

NCT05362045
View directory record Official record
Conditions
Healthy Participants
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
4
States / cities
Miami, Florida • Springfield, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

NCT01178294
View directory record Official record
Conditions
Acquired Hemophilia A
Interventions
OBI-1
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting Not applicable Interventional

Just-in-time Interventions for Reducing Short-term Suicide Risk

NCT05793541
View directory record Official record
Conditions
Suicide
Interventions
Phone call, Text messaging, Automated interactive smartphone-based tool, Non-interactive pop-up messages
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery

NCT00524472
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Hyperinsulinemic-normoglycemic clamp, insulin at the standard of care levels
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
1,439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies

NCT00675831
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
CliniMACS CD25 Reagent Device
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

NCT00694551
View directory record Official record
Conditions
Prostate Cancer
Interventions
Peptide Vaccine, Poly IC-LC
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 25, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional

Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

NCT04004065
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Vesleteplirsen
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 21 Years · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
11
States / cities
Sacramento, California • Farmington, Connecticut • Gulf Breeze, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 25, 2026, 2:58 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

NCT05800015
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
29
States / cities
Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia

NCT00403247
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Capsule with folate, Vitamin B12 & pyridoxine, placebo
Dietary Supplement · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients

NCT00998426
View directory record Official record
Conditions
Hepatitis B
Interventions
glucose monitoring before and after HepaGam B administration, HepaGam B (Hepatitis B Immune Globulin (HBIG))
Procedure · Biological
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 25, 2026, 2:58 PM EDT
Suspended Phase 1Phase 2 Interventional

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT04278768
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Emavusertib, Venetoclax
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain

NCT01530126
View directory record Official record
Conditions
Periodontitis
Interventions
B-TCP + 0.3 mg/ml rhPDGF-BB in buffer, B-TCP + 1.0 mg/ml rhPDGF-BB in buffer, B-TCP +buffer
Biological
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Results available

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

NCT02659943
View directory record Official record
Conditions
Lymphoma, B-Cell, Lymphoma, Non-hodgkins
Interventions
Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adenovirus Vaccine for Malaria

NCT00371189
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
Placebo, Ad35.CS.01 Circumsporozoite Malaria Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
2
States / cities
Stanford, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)

NCT06225414
View directory record Official record
Conditions
Lung Cancer
Interventions
Usual Care, Brief Patient Education, Patient education, Referral to financial navigation resources, Patient Reminders, Provider Reminders
Other · Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
10
States / cities
Anaheim, California • Costa Mesa, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Withdrawn Not applicable Interventional

The Brain Ketone Body Challenge Imaging Study

NCT03204604
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Challenge A - low calorie Ensure®, Challenge B - Ensure® plus ketone esters (KE), PET Scan, Cognitive Testing - FCSRT, Story Recall, BVRT, CogState One Card Learning
Dietary Supplement · Procedure · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 2 Interventional

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

NCT01096043
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting Phase 1 Interventional

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

NCT07600749
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
MK-4884
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
St Louis, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting Phase 1 Interventional

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

NCT06006273
View directory record Official record
Conditions
Refractory Solid Tumors
Interventions
Eribulin, Irinotecan, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Active, not recruiting Phase 1 Interventional

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

NCT03016377
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
Interventions
iC9-CAR19 cells, Rimiducid, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2037
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

NCT06908954
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Palovarotene
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

NCT03082209
View directory record Official record
Conditions
Advanced Solid Tumors, Cancer, Hematologic Malignancies
Interventions
ABBV-621, Venetoclax, Bevacizumab, FOLFIRI
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
New Haven, Connecticut • Chicago, Illinois • Harvey, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 25, 2026, 2:58 PM EDT